INGELHEIM, Germany--(BUSINESS WIRE)--For NON-US, UK & Canada Media Only
The National Institute for Health and Clinical Excellence (NICE) in the United Kingdom has issued a Final Appraisal Determination (FAD)1 recommending the novel oral anticoagulant, Pradaxa® (dabigatran etexilate), as a treatment option without any restrictions within its licensed indication for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation (AF) with one or more risk factors.* The FAD will form the guidance to the National Health Service (NHS) in England and Wales, which is expected to be published in December.
The National Institute for Health and Clinical Excellence (NICE) in the United Kingdom has issued a Final Appraisal Determination (FAD)1 recommending the novel oral anticoagulant, Pradaxa® (dabigatran etexilate), as a treatment option without any restrictions within its licensed indication for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation (AF) with one or more risk factors.* The FAD will form the guidance to the National Health Service (NHS) in England and Wales, which is expected to be published in December.
